All Stories

Sanofi pays $600M upfront for Dren Bio’s bispecific in latest immunology play

The CD20-directed antibody, dubbed DR-0201, is a bispecific myeloid cell engager that Dren has been testing in a phase 1 trial for B-cell non-Hodgkin lymphoma.

Mar 20, 2025 - 11:35
 0
Sanofi pays $600M upfront for Dren Bio’s bispecific in latest immunology play
The CD20-directed antibody, dubbed DR-0201, is a bispecific myeloid cell engager that Dren has been testing in a phase 1 trial for B-cell non-Hodgkin lymphoma.
Read More

Tags:

Previous Article

Branded Residences Forum Asia 2025 to bring global hospitality and real estate l...

Next Article

AMAREA Technology installs its new multi-material MMJ ProX 3D printer at Fraunho...

Related Posts

Tris' next-gen pain drug completes trio of clinical wins, setting up push to FDA

Tris' next-gen pain drug completes trio of clinical win...

Mar 6, 2025  0

Novo Nordisk to sue KBP Biosciences over alleged fraudulent claims on kidney disease drug

Novo Nordisk to sue KBP Biosciences over alleged fraudu...

Feb 18, 2025  0

Fierce Biotech Fundraising Tracker '25: Callio launches with $187M series A; Eikon's eye-catching $350M series D

Fierce Biotech Fundraising Tracker '25: Callio launches...

Mar 3, 2025  0